Adverum Biotechnologies (ADVM) has disclosed a new risk, in the Economy & Political Environment category.
Adverum Biotechnologies faces increased business risk following Brexit, with potential disruptions in its supply chain and regulatory challenges. As the UK diverges from EU regulations, particularly in the area of medicinal products, Adverum may encounter difficulties in product development, approval, and commercialization. This divergence could lead to delays or the inability to obtain necessary approvals, impacting the company’s ability to commercialize product candidates and affecting revenue generation. Moreover, changes in trade regulations may impose additional costs, further challenging Adverum’s business operations and profitability.
Overall, Wall Street has a Moderate Buy consensus rating on ADVM stock based on 2 Buys and 1 Hold.
To learn more about Adverum Biotechnologies’ risk factors, click here.
